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Abstract
There is a predominance of small and dense LDL cholesterol particles in familial combined
hyperlipidemia (FCH). The lipoprotein lipase gene could exert an influence in these circumstances.
To study the relationship of pattern B LDL and lipids with N291S polymorphism of lipoprotein
lipase (LPL) in FCH patients.
Lipid profile, apolipoproteins, diameter of LDL and N291S polymorphism were determined in 93
patients with FCH and 286 individuals from the general population.
FCH patients with N291S polymorphism showed a lower mean diameter of LDL. FCH patients
with pattern B LDL showed higher concentrations of triglycerides, VLDLc, non-HDLc and apo
B100 and lower levels of HDLc than those with pattern A. Of FCH patients with polymorphism
87.5% presented pattern B and 12.5% pattern A, while patients without polymorphism presented
pattern A in 69.2% cases and pattern B in 30.8% cases, with differences being statistically significant
(p < 0.004). The prevalence of this mutation in our FCH patients was 9.7%.
The prevalence of N291S mutation in our FCH patients was similar to the 9.3% described in Dutch
FCHL patients but clearly higher than the 2–5% described for other Caucasian populations. No
polymorphism was found in our general population sample. FCH patients with phenotype B of LDL
possessed an atherogenic lipid profile. The relationship between small and dense LDL and the
presence of the N291S mutation may identify patients with high cardiovascular risk.
Background
A common form of dyslipemia associated with insulin
resistance (obesity, diabetes mellitus, familial combined
hyperlipidemia) is constituted by the presence of the
atherogenic lipoprotein phenotype, characterized by ele-
vated levels of triglycerides, small LDL particles and
reduced HDL cholesterol [1]. This lipid triad frequently
occurs in patients with premature coronary disease [2].
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Small and dense LDL particles are formed largely as a
response to high levels of triglycerides, and increase the
risk of coronary heart disease [3]. LDL particles show a
bimodal distribution in peak size and can be separated
into two phenotypes; pattern A, in which larger, more
buoyant LDL predominate, and pattern B, in which
smaller, more dense LDL predominate. The National
Cholesterol Education Program (ATP III) considers small
and dense LDL as a lipid risk factor.
Familial Combined Hyperlipidemia (FCH; MIM 144250) is
the most frequent genetic hyperlipemia. It is characterized by
a tendency towards the appearance of coronary disease
before 60 years of age [4]. The prevalence of this disease is 1–
2% in the general population [5] and 10–20% among
patients with premature coronary disease [6]. FCH presents
a complex phenotype that is not completely understood,
and which can vary between the patient and affected relatives
[7]. Therefore, it is difficult to diagnose. It is also character-
ized by the presence of the atherogenic lipoprotein pheno-
type and an increase in apolipoprotein B100 [8].
Several genes have been studied in relation with FCH,
which is a polygenic disease. One of the genes involved in
FCH is lipoprotein lipase (LPL, E.C. 3.1.1.34) [9], a glyco-
proteic enzyme that plays a key role in the catabolism of
lipoproteins rich in triglycerides, such as chylomicrons,
and very low density lipoproteins (VLDL). LPL action
takes place in endothelial cells surrounding the lumen of
capillary vessels, where it adheres to heparan sulphate
proteoglycans [10].
More than 80 structural mutations have been detected
within the LPL gene. The frequency of these mutations in
the general population is estimated to be at least 1/500.
These heterozygous mutations are the main cause of some
lipid disorders. One of these mutations is N291S localized
in exon 6 of LPL [11-13].
The aim of our study was to analyze the relationship of the
atherogenic lipoprotein profile, especially the predomi-
nance of small and dense LDL, with the prevalence of
N291S LPL polymorphism in Spanish patients with FCH
from the Community of Valencia with respect to with the
general population.
Materials and methods
Our study sample consisted of 33 families with Familial
Combined Hyperlipidemia (FCH), with a mean of 4.4
individuals per family, all of them living in the Autono-
mous Community of Valencia (SE of Spain). From a total
of 146 subjects, 93 were diagnosed with FCH according to
the criteria of Bredie SJ et al. [14]. Total cholesterol and
triglycerides levels superior to the 90th  percentile
(adjusted to age and gender) and apo B100 values supe-
rior to 1.2 g/L represented a diagnosis of FCH in 43 men
and 50 women, aged from 15 to 75 years. In order to
assess polymorphism in the general population, 286
genetically independent healthy controls of similar gen-
der and age were randomly selected.
Venous blood was collected for biochemical measure-
ments. Total cholesterol (TC) and triglycerides (TG) were
measured through enzymatic methods and high density
lipoproteins cholesterol (HDLc) using a direct method in
a Beckman LX20 auto analyzer. The intraserial variation
coefficient was < 3.5% for all these determinations. When
TG values were under 400 mg/dL, LDL cholesterol con-
centration was calculated using Friedewald's formule [15].
Non-HDL cholesterol was obtained from the difference
between total cholesterol and HDL cholesterol. Apolipo-
proteins AI and B100 were determined by immunoneph-
elometry in a Dade Behring BNII (intra-assay variation
coefficient < 5.5%).
LDL B phenotype was measured by polyacrylamide gradi-
ent gel electrophoresis (2–16%) using the methodology
described by Nichols et al. [16]. The assignment of LDL
subclass phenotypes was based on particle diameter: pat-
tern A, mean diameter > 25.5 nm, and pattern B, predom-
inance of small and dense particles with a mean diameter
≤ 25.5 nm [17].
Approval was obtained from the relevant institutional
review board, and all participants gave their informed
consent.
DNA analysis for RFLP detection in LPL
DNA was extracted from tubes of 15 mL of blood with
EDTA-K3, according to the method of Miller et al. [18],
and was conserved at 4°C until analysis was performed.
N291S was identified after PCR amplification of a 238 bp
fragment using the following oligonucleotides: forward 5'
GCCGAGATACAATCTTGGTG 3' and reverse 5' CTGCT-
TCTTTTGGCTCTGACTGT 3'. Such a polymorphism adds
a restriction site for the Ava II enzyme. PCR reaction was
performed in 25 μl total volume containing 0.3 mM of
each primer, 0.2 mM of each dNTP, 1× Taq buffer, 2 mM
MgCl2, 100 ng of genomic DNA and 2.5 U Taq polymer-
ase (Netzyme) in a Master-Cycler thermocycler (Eppen-
dorf). PCR was performed by means of a touchdown
protocol [19] according to the following conditions: an
initial denaturation step of 10 minutes at 94°C was fol-
lowed by 4 cycles of 30 seconds at 94°C, 30 seconds at
60°C and 45 seconds at 72°C. This was followed by 20
cycles of 30 seconds at 94°C, 30 seconds at 60°C minus
0.5°C in each cycle and 45 seconds at 72°C, and then 10
cycles of 30 seconds at 94°C, 30 seconds at 50°C and 45
seconds at 72°C. The final extension consisted of 10 min-
utes at 72°C. The PCR product was digested for 4 hours at
37°C with Ava II and then analyzed with an 8% polyacr-Lipids in Health and Disease 2009, 8:12 http://www.lipidworld.com/content/8/1/12
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ylamide gel. If the polymorphism was present, two frag-
ments of 215 and 23 bp (HT+) appeared; if not, the site
was destructed in the normal chain, which remained non-
digested (238 bp: WT).
Study design
The study was conducted based on a case-control design.
Ninety-three FCHL patients were recruited and matched
according to sex and age with a control group of 286 sub-
jects from the general population.
Statistics
Between-groups comparison was performed using an
ANOVA followed by a parametric t-test. Due to skewed
distribution of TG, TG analyses were performed on loga-
rithmically transformed values. Statistical analyses were
carried out using the Microsoft Excel Data Analysis Pack-
age (Microsoft, Inc.).
The Mann-Whitney nonparametric test was used to com-
pare lipid concentrations in FCH patients with pattern A
and those with pattern B. To test differences in triglycer-
ides levels, values were logarithmically transformed prior
to statistical analysis.
χ2 was performed in order to determine whether popula-
tions were in Hardy-Weinberg equilibrium and in order to
compare different phenotypes. Significance was set at p <
0.05.
Statistic analyses were carried out using the SSPS-15.0 pro-
gram for Windows (SPSS Inc., Chicago, IL).
Results
A total of 93 patients, all diagnosed with FCH, were stud-
ied: 43 men (46.3%) and 50 women (53.7%), aged
between 15 and 75. 286 subjects from the general popu-
lation were also studied. Lipid parameters are expressed in
Table 1. Significant differences were observed between the
two groups in all the variables studied. FCH patients
showed higher levels of total cholesterol, triglycerides,
LDLc, non-HDLc and apo B100, and lower levels of
HDLc, apo A and a smaller LDL diameter.
When non-mutated wild-type (WT) and heterozygote
(HT) patients were compared, a smaller average diameter
of LDL particles was observed among the latter, with the
difference being statistically significant. Table 2 shows the
lipid values of pattern A patients compared to those of
pattern B patients. FCH patients with pattern B LDL dis-
played higher concentrations of triglycerides, VLDLc, non-
HDLc and apo B100 and lower levels of HDLc than FCH
patients with pattern A.
Patients with polymorphism presented pattern B in
87.5% of cases and pattern A in 12.5% of cases, while
patients without polymorphism presented pattern A in
69.2% of cases and pattern B in 30.8% of cases. These dif-
ferences were statistically significant (p < 0.004).
N291S polymorphism of LPL occurred in 9.7% of FCH
patients, while no individual in the study sample from the
general population presented this mutation. Both sam-
ples were in Hardy-Weinberg equilibrium, as the patients
showed a χ2 = 0.216 and 2p = 0.6423 and the general pop-
ulation a χ2 = 0 and 2p = 1.
Discussion
FCH is a disease with a complex phenotype that is not
completely understood, and remains difficult to diagnose.
This dyslipemic syndrome is associated with disturbances
in all lipoprotein fractions. The key underlying abnormal-
ity of this condition is elevation of VLDL due to overpro-
duction or defective catabolism [20]. Small and dense
LDL is the final expression of this catabolism. These parti-
cles are more easily oxidized and display a higher affinity
for the extracellular matrix and a higher degree of reten-
tion in arterial wall than their larger, normal-sized coun-
Table 1: Lipid concentrations in cases (FCH patients) and 
controls.
FCH Patients Controls P value*
Total cholesterol 238.67 ± 50.10 185.13 ± 28.30 0.001
Triglycerides 204.71 ± 192.16 88.27 ± 42.45 0.001
LDLc 156.85 ± 39.97 113.50 ± 25.20 0.001
HDLc 47.77 ± 17.18 53.93 ± 14.48 0.001
VLDLc 40.28 ± 36.52 17.65 ± 8.49 0.001
Non-HDLc 192.94 ± 48.68 131.50 ± 29.09 0.001
Apo AI 133.55 ± 32.52 152.79 ± 29.03 0.001
Apo B100 125.80 ± 28.11 95.25 ± 21.15 0.001
LDL diameter 25.45 ± 0.78 26.14 ± 0.74 0.001
* ANOVA Test
Values are expressed as mean ± standard deviation. Units are mg/dL 
in all parameters except LDL diameter (nm).
Table 2: Lipid concentrations in FCH patients with pattern A and 
pattern B
Pattern A (n = 26) Pattern B (n = 27) P-value*
Total cholesterol 227.88 ± 41.86 238.03 ± 50.86 0.450
Triglycerides 127.80 ± 65.77 344.55 ± 234.40 0.001
HDLc 55.00 ± 18.54 35.59 ± 7.94 0.001
LDLc 147.50 ± 34.64 149.06 ± 53.11 0.569
VLDLc 25.53 ± 13.11 65.34 ± 43.71 0.001
Non-HDLc 172.88 ± 32.40 202.44 ± 50.71 0.022
Apo AI 144.00 ± 39.87 121.33 ± 20.49 0.029
Apo B100 118.13 ± 22.22 133.69 ± 30.21 0.042
ApoB/ApoA 0.90 ± 0.29 1.50 ± 0.35 0.022
Diameter 26.06 ± 0.57 24.86 ± 0.42 0.001
* Mann-Whitney test
Values expressed as mean ± Standard Deviation. Units are mg/dL in all 
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terparts [21]. Small and dense LDL has been accepted as
an emergent cardiovascular risk factor by the National
Cholesterol Education Programme (Adult Treatment
Panel III) [22], as many studies have demonstrated that
the predominance of these particles is associated with an
increase in cardiovascular risk more than classic lipid var-
iables [23,24]. FCH patients with phenotype B of LDL
show a clearly atherogenic lipid profile. There is evidence
that hypolipidemic treatment can modify the distribution
of LDL subclasses [25]. Very high risk patients, including
those with this atherogenic lipoprotein profile, may ben-
efit from more potent lipid-lowering therapies [26].
It has been suggested that FCH is a heterogeneous and oli-
gogenic disease [27]. One of the genes likely to exert an
influence in this disease is the lipoprotein lipase gene.
Many codon polymorphisms of the LPL gene have been
described, some of them associated with alterations of the
metabolism of triglyceride-rich lipoproteins [28]. One of
the most frequent polymorphisms is located in exon 6
(rs268, c. 1128 A>G; N291S) [29]. The prevalence of this
mutation in our FCH patients was 9.7%, which is similar
to the 9.3% described for Dutch FCH patients [5] but con-
siderably higher than the 2–5% described for other Cau-
casian populations [30]. No polymorphism was detected
in the sample from the general population, which reflects
findings in other populations [5] in which no carriers
were found, suggesting that the N291S mutation is more
frequent among FCH patients. The mutation is likely to
affect postprandial lipemia by altering its enzymatic activ-
ity [31], resulting in an increase of VLDL particles and
high concentrations of apo B100 and leading to the
appearance of a greater number of small and dense LDL
particles as the final and most important expression of the
catabolism of triglyceride-rich lipoprotein particles [32].
In this way, the FCH phenotype of patients with the poly-
morphism is negatively affected, with altered postpran-
dial responses to fat-rich meals being described, even in
patients that were initially normolipemic [33].
These previously published data coincide with our results;
polymorphism-carrier patients have been reported to
present a smaller LDL diameter, suggesting a clearly ather-
ogenic alteration of the metabolism of triglyceride-rich
particles [34]. In fact, in some studies regarding FCH, this
polymorphism has been related to patients who had pre-
viously presented an ischemic cardiopathy [11].
In our study, patients with the N291S polymorphism
showed a smaller average LDL diameter, corresponding
with pattern B and constituting the final expression of the
alteration of the metabolism of triglyceride-rich particles.
This represents a higher cardiovascular risk among such
patients. On the other hand, most patients without this
polymorphism had pattern A, constituting a clear differ-
ence between both groups. We are aware of the limita-
tions of this study in relation to the number of patients
with the polymorphism. Unfortunately, its low preva-
lence among the general population makes it difficult to
conduct a genetic study with a large number of patients
that would permit us to draw more solid conclusions.
That said, our data show important differences between
the two patterns.
In conclusion, FCH patients with pattern B of LDL show a
clearly atherogenic lipid profile. The relationship between
small and dense LDL and the presence of the allele encod-
ing for N291S mutation of the LPL gene, present in a high
percentage of our FCH patients, could disrupt the pheno-
type of the disease by altering the clearance of triglyceride-
rich lipoproteins. Such phenotype expression is the basis
for a more atherogenic profile. Therefore, based on our
results in FCH patients in the Autonomous Community
of Valencia, the cardiovascular risk of those with pattern B
of LDL who carry this polymorphism could be considera-
bly reduced through rigorous treatment of Hyperlipemia.
Abbreviations
FCH: Familial combined hypermipidemia; LPL: lipopro-
tein lipase; WT: non-mutated wil-type; HT: Heterzygote.
Competing interests
The authours declare that they have no competing inter-
ests.
Authors' contributions
AH-M, AL-R and MM-T participated in the design of the
study, MJ, AL-R and MM-T carried out the laboratory stud-
ies. CB and MM performed the statistical analysis and
interpretation of data. MC and AL-R carried out the
molecular genetic studies. ES and AH-M have been
involved in the revision of the manuscript. All authors
read and approved the final manuscript.
Acknowledgements
MC was supported by grant SAF2006-06760 from CICYT,
Spain and by a grant from Instituto de Salud Carlos III
(Red de Centros FIS-RECAVA RD06/0014/0025).
References
1. Grundy SM: Hypertriglyceridemia, atherogenic dyslipidemia
and the metabolic syndrome.  Am J Cardiol 1998,
81(4A):18B-25B.
2. Austin MA, King MC, Vranizan KM, Krauss RM: Atherogenic lipo-
protein phenotype. A proposed genetic marker for coronary
heart disease risk.  Circulation 1990, 82:495-506.
3. St-Pierre AC, Cantin B, Dagenais GR, Mauriège P, Bernard PM,
Després JP, Lamarche B: Low-density lipoprotein subfractions
and the long-term risk of ischemic heart disease in men: 13-
year follow-up data from the Quebec Cardiovascular Study.
Arterioscler Thromb Vasc Biol 2005, 25:553-559.
4. Eurlings PM, Kallen CJ van der, Geurts JM, van Greevenbroek MM, de
Bruin TW: Genetic dissection of familial combined hyperlipi-
demia.  Mol Genet Metab 2001, 74:98-104.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Lipids in Health and Disease 2009, 8:12 http://www.lipidworld.com/content/8/1/12
Page 5 of 5
(page number not for citation purposes)
5. Hoffer MJV, Bredie SJH, Boomsma DI, Reymer PWA, Kastelein JJP, de
Knijff P, Demacker PNM, Stalenhoef AFH, Havekes LM, Frants RR:
The lipoprotein lipase (Asn291-Ser) mutation associated
with elevated lipid level families with familial combined
hyperlipidaemia.  Atherosclerosis 1996, 119:159-167.
6. Goldstein JL, Schrott HG, Hazzard WR, Bierman EL, Motulsky AG:
Hyperlipidemia in coronary heart disease II. Genetic analysis
of lipid levels in 176 families and delineation of a new inher-
ited disorder, combined hyperlipidemia.  J Clin Invest 1973,
52:1544-1568.
7. Porkka KV, Nuotio I, Pajukanta P, Ehnholm C, Suurinkeroinen L,
Syvänne M, Lehtimäki T, Lahdenkari AT, Lahdenperä S, Ylitalo K,
Antikainen M, Perola M, Raitakari OT, Kovanen P, Viikari JS, Peltonen
L, Taskinen MR: Phenotype expression in familial combined
hyperlipidemia.  Atherosclerosis 1997, 133:245-253.
8. Ayyobi AF, McGladdery SH, McNeely MJ, Austin MA, Motulsky AG,
Brunzell JD: Small, dense LDL and elevated apolipoprotein B
are the common characteristics for the three major lipid
phenotypes of familial combined hyperlipidemia.  Arterioscler
Thromb Vasc Biol 2003, 23:1289-1294.
9. Hu Y, Liu W, Huang R, Zhang X: A systematic review and meta-
analysis of the relationship between lipoprotein lipase
Asn291Ser variant and diseases.  J Lipid Res 2006, 47:1908-1914.
10. Enerback S, Gimble JM: Lipoprotein lipase gene expression:
physiological regulator at the transcriptional and post-tran-
scriptional level.  Biochem Biophys Acta 1993, 1169:107-125.
11. Gerdes C, Fisher RM, Nicaud V, Boer J, Humphries SE, Talmud PJ,
Faergeman O: Lipoprotein lipase variants D9N and N291S are
associated with increased plasma triglyceride and lower
high-density lipoprotein cholesterol concentrations: studies
in the fasting and postprandial states: the European Athero-
sclerosis Research Studies.  Circulation 1997, 96:733-740.
12. Wittrup HH, Tybjaerg-Hansen A, Abildgaard S, Steffensen R, Schnohr
P, Nordestgaard BG: A common substitution (Asn291Ser) in
Lipoprotein Lipase is associated with increased risk of
ischemic heart disease.  J Clin Invest 1997, 99:1606-1613.
13. Reymer PW, Groenemeyer BE, Gagné E, Miao L, Appelman EE, Seidel
JC, Kromhout D, Bijvoet SM, Oever K van de, Bruin T, Hayden MR,
Kastelein JJP: A frequently occurring mutation in the lipopro-
tein lipase gene (Asn291Ser) contributes to the expression
of familial combined hyperlipidemia.  Hum Mol Genet 1995,
4:1543-1549.
14. Bredie SJ, Demacker PN, Stalenhoef AF: Metabolic and genetic
aspects of familial combined hyperlipidaemia with emphasis
on low-density lipoprotein heterogeneity.  Eur J Clin Invest 1997,
27:802-811.
15. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the con-
centration of low-density lipoprotein cholesterol in plasma
without use of preparative ultracentrifuge.  Clin Chem 1972,
18:499-502.
16. Nichols AV, Krauss RM, Musliner TA: Nondenaturing polyacryla-
mide gradient gel electrophoresis.  Methods Enzymol 1986,
128:417-431.
17. Austin MA, Hokanson JE, Brunzell JD: Characterization of low-
density lipoprotein subclasses: methodologic approaches
and clinical relevance.  Curr Opin Lipidol 1994, 5:395-403.
18. Miller SA, Dykes DD, Polesky HF: A simple salting out procedure
for extracting DNA from human nucleated cells.  Nucleic Acids
Res 1988, 16(3):1215.
19. Hecker KH, Roux KH: High and low annealing temperatures
increase both specificity and yield in touchdown and step-
down PCR.  Biotechniques 1996, 20:478-485.
20. Adiels M, Olofsson SO, Taskinen MR, Borén J: Overproduction of
very low-density lipoproteins is the hallmark of the dyslipi-
demia in the metabolic syndrome.  Arterioscler Thromb Vasc Biol
2008, 28:1225-1236.
21. Packard CJ: Small dense low-density lipoprotein and its role as
an independent predictor of cardiovascular disease.  Curr Opin
Lipidol 2006, 17:412-417.
22. Rajman I, Eacho PI, Chowienczyk PJ, Ritter JM: LDL particle size:
an important drug target?  Br J Clin Pharmacol 1999, 48:125-133.
23. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunning-
hake DB, Pasternak RC, Smith SC Jr, Stone NJ, National Heart, Lung,
and Blood Institute; American College of Cardiology Foundation;
American Heart Association: Implications of recent clinical trials
for the National Cholesterol Education Program Adult
Treatment Panel III Guidelines.  Circulation 2004, 110:227-239.
24. Jarvik GP, Brunzell JD, Austin MA, Krauss RM, Motulsky AG, Wijsman
E: Genetic predictors of FCH in four large pedigrees. Influ-
ence of ApoB level major locus predicted genotype and LDL
subclass phenotype.  Arterioscler Thromb 1994, 14:1687-1694.
25. Nevin DN, Brunzell JD, Deeb SS: The LPL gene in individuals
with familial combined hyperlipidemia and decreased LPL
activity.  Arterioscler Thromb 1994, 14:869-873.
26. Van Bockxmeer FM, Liu Q, Mamotte C, Burke U, Taylor R: Lipopro-
tein lipase D9N, N291S and S447X polymorphisms: their
influence on premature coronary heart disease and plasma
lipids.  Atherosclerosis 2001, 157:123-129.
27. Wittekoek ME, Pimstone SN, Reymer PW, Feuth L, Botma GJ, Defe-
sche JC, Prins M, Hayden MR, Kastelein JJ: A common mutation in
the lipoprotein lipase (N291S) alters the lipoprotein pheno-
type and risk for cardiovascular disease in patients with
familial hypercholesterolemia.  Circulation 1998, 97:729-735.
28. Razzaghi H, Day BW, McClure RJ, Kamboh MI: Structure-function
analysis of D9N and N291S mutations in human lipoprotein
lipase using molecular modelling.  J Mol Graph Model 2001, 19:.
487–494, 587–590.
29. Georgieva AM, van Greevenbroek MM, Krauss RM, Brouwers MC,
Vermeulen VM, Robertus-Teunissen MG, Kallen CJ van der, de Bruin
TW: Subclasses of low-density lipoprotein and very low-den-
sity lipoprotein in familial combined hyperlipidemia: rela-
tionship to multiple lipoprotein phenotype.  Arterioscler Thromb
Vasc Biol 2004, 24:744-749.
30. Pimstone SN, Clee SM, Gagne SE, Miao L, Zhang H, Stein EA, Hayden
MR: A frequently occurring mutation in the lipoprotein lipase
gene (Asn291Ser) results in altered postprandial chylomi-
cron triglyceride and retinyl palmitate response in normoli-
pidemic carriers.  J Lipid Res 1996, 37:1675-1684.
31. Hopkins PN, Heiss G, Ellison RC, Province MA, Pankow JS, Eckfeldt
JH, Hunt SC: Coronary artery disease risk in familial combined
hyperlipidemia and familial hypertriglyceridemia: a case-
control comparison from the National Heart, Lung, and
Blood Institute Family Heart Study.  Circulation 2003,
108:519-523.
32. National Cholesterol Education Program (NCEP): Expert Panel on
Detection, Evaluation, and Treatment of High Blood Cholesterol in
Adults (Adults Treatment Panel III): Third Report of the National
Cholesterol Education Program (NCEP): Expert Panel on
Detection, Evaluation, and Treatment of High Blood Choles-
terol in Adults (Adults Treatment Panel III) final report.  Cir-
culation 2002, 106:3143-3421.
33. Vakkilainen J, Steiner G, Ansquer JC, Aubin F, Rattier S, Foucher Ch,
Hamsten A, Taskinen MR, DAIS Group: Relationships between
low-density lipoprotein particle size, plasma lipoproteins,
and progression of coronary artery disease: the Diabetes
Atherosclerosis Intervention Study (DAIS).  Circulation 2003,
107:1733-1737.
34. Hurt-Camejo E, Camejo G, Sartipy P: Phospholipase A2 and
small, dense low-density lipoprotein.  Curr Opin Lipidol 2000,
11:465-471.